The prevention of tuberculosis (TB) is an important global public health issue. Patients with malignant diseases are more vulnerable to tuberculosis because of their immunocompromised status. Therefore, for tuberculosis in patients with malignant diseases, the necessity and timing of treatment need to be carefully assessed. While often affecting the lungs, tuberculosis can also spread to the other parts of the body, resulting in extrapulmonary tuberculosis (EPTB). Though medication is basically the same, TB and EPTB differ from each other in terms of treatment duration and isolation method.
This was a case of ampulla of Vater cancer. Peritoneal carcinomatosis and peritoneal tuberculosis were found during operation. As her condition deteriorated quickly, the patient received no anti-tuberculosis therapy but was isolated to prevent potential spread from abdominal lesion. The patient was subsequently sent to hospice ward for palliative care. As indicated by the case, for infection and disease control, a patient with a malignant disease and tuberculosis infection should receive anti-tuberculosis therapy. However, if the patient is terminally ill, the medical team should discuss with the family to reach a consensus about the use of medication, the implementation of isolation, and the need for psychological and spiritual care so as to provide the patient with better end-of-life care.